127 results about "Cellular secretion" patented technology

The invention provides brain cell specific targeting delivery based on exosome, and the exosome secreted by 293T cells is used for engineering transformation, so that the capabilities of penetrating BBB and specifically targeting neurons are achieved. According to the present invention, the L1CAM is loaded on the exosome, the exosome is obtained by transfecting a 293T cell of a Lamp2b-L1CAM PCDH-HygroHA plasmid through a 293T-Lamp2b-L1CAM cell line, and the BBB cell-penetrating peptide 4F-T7 and the neuronal targeting protein L1CAM are loaded on the surface of the exosome so as to treat the neurodegenerative diseases such as the Alzheimer's disease and the Parkinson's disease.

The invention relates to the technical field of medical cosmetology, in particular to a porous hollow glass bead capable of slowly releasing collagen and application of the porous hollow glass bead. The porous hollow glass bead capable of slowly releasing the collagen comprises a porous hollow glass bead body, the outer wall of the porous hollow glass bead body is provided with a pore channel structure penetrating through the exterior and an inner cavity of the hollow glass bead body, and the pore channel and the inner cavity of the porous hollow glass bead body are filled with collagen gel. The compressive strength of the hollow glass beads is utilized to improve the mechanical supporting effect, the collagen gel is subjected to catalytic decomposition under the action of collagenase in a body so as to achieve the slow-release effect, the outer walls of the hollow glass beads slow down the reaction time through physical isolation, and then the slow-release time is prolonged; meanwhile, ions such as Si and Ca released by the hollow glass beads can promote cells to secrete collagen, the biological activity is improved, and the three beneficial effects of physical support, collagen slow release and biological safety are achieved.

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

The present invention relates to the new use of an exosome secreted by hepatocyte lineage cells differentiated via the directed induction of embryonic stem cells, and in particular relates to the use of the exosome in the preparation of a drug for treating liver diseases. The exosome is secreted by hepatocyte lineage cells differentiated via the directed induction of embryonic stem cells, and the hepatocyte lineage cells are hepatic progenitor cells and / or mature hepatocyte-like cells.

The invention relates to a micro-fluidic chip for chemiluminescence imaging detection of single-cell secretions and a use method of the micro-fluidic chip. The micro-fluidic chip is composed of a single cell analysis layer and a glass substrate layer. The single cell analysis layer is prepared from polydimethylsiloxane and is provided with a capture channel, a sample introduction channel and a lantern-shaped microstructure array, the lantern-shaped microstructure comprises a small-size cell capture trap and a large-size chemiluminescence detection chamber, the small-size cell capture trap is connected with the capture channel, and the large-size chemiluminescence detection chamber is connected with the sample introduction channel. After a mixed solution of cells and a detection reagent is introduced into the capture channel, single cell capture is realized on the capture trap due to flow resistance difference; then, introducing air into the capture channel and the sample introduction channel to form a gas-in-liquid microcavity, and carrying out single cell isolation and incubation reaction; finally, the signal switch molecules and the substrate liquid are sequentially injected into the chemiluminescence detection chamber through the sample injection channel, and quantitative detection is conducted on the single-cell secretions according to chemiluminescence imaging signals.

The application belongs to the technical field of medicine, and discloses a class of alkaloid compounds and the use of pharmaceutical compositions thereof in treating inflammation. In vitro cell experiments prove that the components have a significant inhibitory effect on the secretion of important inflammatory factors TNF-alpha and NO of lipopolysaccharide-induced RAW264.7 cells, and have a significant down-regulation effect on the phosphorylation level of key proteins of the NF-kappa B pathway in the inflammatory state. In vivo animal experiments prove that the components have a significant inhibitory effect on the tincture of croton oil-induced mouse ear swelling, and can be used for preventing and / or treating inflammation-related diseases.

The invention belongs to the technical field of exosomes, and discloses an exosome preparation method and application, the exosome preparation method comprises the following steps: S1, culturing target cells in an induction medium, and collecting the cells and a culture solution; s2, separating the culture solution to obtain supernate A and cell precipitate; s3, performing chromatographic purification and concentration on the supernate A to obtain the exosome; in the step S1, colchicine is also added in the process of culturing the target cells to synchronize the cell cycle; a polycaprolactone-gelatin composite microcarrier is suspended in the induction culture medium, and nicotinamide, an epidermal growth factor (EGF) and pyruvic acid are contained in the induction culture medium; the method further comprises a step S30 before the step S3, resuspending the cell precipitate obtained in the step S2 with a vesicle protection solution containing trehalose, sucrose and EDTA to obtain a supernatant B, and then combining the supernatant A with the supernatant B. According to the preparation method provided by the invention, the total secretion amount of target cells is large, the intracellular vesicle-exosome precursor can be collected, and the obtained exosome is high in concentration and low in impurity content.

A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

This invention relates to a pharmaceutical composition for treating autoimmune diseases. The pharmaceutical composition for treating autoimmune diseases comprises an antibody and an inhibitor, wherein the antibody includes at least one of an OX40 antibody and an OX40L antibody, and the inhibitor includes at least one of a Janus kinase inhibitor and a RORγt inhibitor. In the above-mentioned pharmaceutical composition for treating autoimmune diseases, the Janus kinase inhibitor and / or the RORγt inhibitor can inhibit the secretion of IL17A by Treg cells induced by OX40 antibody and / or OX40L antibody, thereby reducing IL17A-promoted pathological inflammation and improving the efficacy of OX40 antibody and / or OX40L antibody in treating autoimmune diseases.

A reagent, a drug source material, a drug, a quasi-drug, a cosmetic source material, or a cosmetic that includes a supernatant of a culture solution of stem cells and is for reducing skin redness or inflammation, inflammation, number of pores, pore size, skin spots, and sebum. A reagent, a drug source material, a drug, a quasi-drug, a cosmetic source material, or a cosmetic that includes a secretion of stem cells and is for reducing skin redness or inflammation, inflammation, number of pores, pore size, skin spots, and sebum. The secretion of the stem cells may be extracellular vesicles. The secretion of the stem cells may be exosomes.

The present application provides a kind of oil composition, containing monounsaturated fatty acid, polyunsaturated fatty acid, monounsaturated fatty acid is omega-9 fatty acid;Polyunsaturated acid is the mixture of omega-6 fatty acid and omega-3 fatty acid.The present application can repair and resist aging, all-purpose skin care, increase epidermal thickness, enhance barrier, anti-inflammatory soothing, anti-wrinkle firming, soothing repair red, nourish skin, and can be applied to sensitive skin, can inhibit LPS-induced HaCaT cell IL-6 secretion, increase the thickness of 3D skin model epidermis layer, and can promote the expression of silk aggregate protein (FLG), ceramide synthase 3 (CerS3), desmoglein core glycoprotein (DSG1) which has important role for skin barrier function, indicating that it can alleviate the inflammatory response produced by LPS stimulation HaCaT cell and has enhanced skin barrier function.

The invention relates to a single-cell secretion group sample treatment device and preparation and application thereof, the device is composed of two parts: the first part is a single-cell control chip which can realize capture and culture of single cells and separation and collection of a culture solution; the second part is a propargyl functionalized capillary microreactor which can realize high-selectivity enrichment and in-situ enzymolysis of single-cell secreted protein; the two parts are integrated to construct the single cell secretion group sample treatment device. The device is combined with a high-sensitivity liquid chromatography-mass spectrometry technology, large-scale quantitative analysis of a single cell secretion group can be realized, and an important means is provided for functional heterogeneity analysis of single cells.

Systems, methods, compositions, and kits for measuring secreted factors from cells are disclosed herein, including those capable of determining single cell secretion activity and protein expression and / or gene expression simultaneously. Disclosed herein include solid supports comprising a plurality of capture probes capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. Also disclosed herein include secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe. A secreted factor-binding reagent can comprise a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.

This invention discloses a preparation process for a homogeneous immunomodulatory polysaccharide from *Gynostemma pentaphyllum* and its application in the preparation of anti-melanoma drugs and immunomodulators, relating to the field of pharmaceutical manufacturing technology. The preparation process includes four steps: compound enzyme-ultrasound synergistic extraction, fractional alcohol precipitation to remove proteins, DEAE-52 ion exchange column chromatography, and Sephacryl S-400 gel permeation chromatography purification. The resulting homogeneous polysaccharide (GOP-3) has a weight-average molecular weight of 12±1 kDa and is composed of mannose, glucose, and galactose in a specific ratio. The GOP-3 of this invention has a weight-average molecular weight (Mw) of 12.8 kDa, a dispersion (Mw / Mn) < 1.2, a uronic acid content of 23.5%, a well-defined structure, and is suitable for drug application. Furthermore, GOP-3 can significantly promote the secretion of IL-12 by dendritic cells and induce the differentiation of naive T cells into Th1 cells. Simultaneously, compared with a full-dose PD-1 monoclonal antibody, the combination of GOP-3 and a half-dose monoclonal antibody not only reduces the risk of immune-mediated pneumonia caused by antibody drugs but also increases the tumor inhibition rate by more than 40%.

The invention provides an umami peptide without nervous excitatory toxicity and a preparation process and application thereof, the umami peptide is extracted from broad bean protein, and the amino acid sequence is shown as SEQ ID NO.1 and / or SEQ ID NO.2. Compared with a traditional umami substance-sodium glutamate (monosodium glutamate MSG), the umami peptide has the characteristics of activating umami receptors TAS1R1 / TAS1R3 without acting on sodium glutamate receptors such as NMDA and the like, and has the advantages that the umami peptide can be used for preparing the umami peptide. No NMDA receptor mediated excitatory neurotoxicity exists; meanwhile, the umami peptide can stimulate intestinal endocrine cells (STC-1) to secrete GLP-1.

The invention discloses a metagen which is prepared from bifidobacterium longum CCFM1508 and has the effects of regulating skin ceramide de novo synthesis and improving skin health, and belongs to the technical field of microorganisms and medicines. The bifidobacterium longum CCFM1508 and the metagen prepared from the bifidobacterium longum CCFM1508, provided by the invention, have the effects of promoting ceramide synthesis and improving skin health by external use and oral administration, and are specifically shown as follows: a thallus lysate and a fermented supernatant of the bifidobacterium longum CCFM1508 can promote HaCaT cells to secrete ceramide in the aspect of external use, and the thallus lysate can remarkably improve the activity of the HaCaT cells. And the viable bacteria and the postbiotics of the bifidobacterium longum CCFM1508 which are orally taken have obvious effects in skin apparent indexes, the content of cerayl and proinflammatory factors. Therefore, the bifidobacterium longum has huge application prospects in preparation of external or oral medicines for promoting synthesis of skin ceramide and improving skin health and preparation of food, health care products or cosmetics.

The invention relates to the technical field of microfluidics, and particularly discloses a cell communication micro-fluidic chip with a cell capturing structure and application of the cell communication micro-fluidic chip. The chip comprises main channels, and the two main channels are arranged in parallel at an interval; the cell interception structures are arranged in the main channels, grooves capable of accommodating at least one cell to be cultured are formed in the incident flow surfaces in the main channels, and at least one opening only allowing a culture solution to flow out is formed in each groove, so that the cells can stably stay and are uniformly distributed, and meanwhile, fluid is allowed to pass through; the culture solution interaction structure is arranged between the two main channels and used for interaction of culture solutions in the two main channels, transverse exchange of the culture solutions and cell secretions is achieved, cell migration is prevented at the same time, and therefore the non-contact cell communication model is constructed. The cell communication micro-fluidic chip can efficiently simulate the cell paracrine communication process, and is suitable for various cell communication research scenes such as inflammatory response, immune regulation, tumor microenvironment, stem cell secretion factor effect and the like.

The present invention relates to a composition, for prevention or treatment of cancer diseases, comprising CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as an active ingredient. It was found that the secretion of extracellular vesicles from cytokine-activated CD4+ T cells increases and the extracellular vesicles enhance proliferation and activity of CD8+ T cells to induce the death of cancer cells, thereby augmenting an anticancer effect. Thus, the present invention provides the CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as a pharmaceutical agent or an immunotherapeutic agent for cancer diseases, and a method for activating CD8+ T cells by using CD4+ T cell-derived extracellular vesicles to prepare CD8+ T cells showing excellent anticancer activity as described above.

The invention provides a micro-fluidic electrical stimulation chip device and a system and method for promoting cells to secrete exosomes by using the micro-fluidic electrical stimulation chip device, the on-line electrical stimulation treatment of the cells can be carried out in the normal suspension culture process of the cells, and cell suspensions flowing through a plurality of micro-channels in the micro-fluidic electrical stimulation chip are stimulated by electrical signals, so that the exosomes are secreted by the cells. Cells are promoted to secrete exosomes, and the yield of the exosomes is increased.

The invention relates to a culture method for reducing the polymer content in a CHO cell bispecific antibody, CHO cells are inoculated into a culture medium for cell culture, a regulator is added in the cell culture process, culture is performed at the temperature of 35-37.5 DEG C so as to reduce the polymer content of the CHO cell secreted bispecific antibody, and the regulator is selected from cystine or cysteine. According to the method, in a cell culture process flow, the temperature and the additive amount of the regulator can be regulated according to requirements, so that the polymer content of the bispecific antibody is regulated, the growth and expression of cells are not influenced, the generation of the polymer in the bispecific antibody is inhibited, the polymer content is obviously reduced, and the cell culture efficiency is improved. The product quality of the bispecific antibody is obviously improved.

The invention belongs to the technical field of targeted drugs, and particularly relates to a 293T exosome for targeted delivery of pirfenidone through a membrane-loaded FAP and a preparation method and application thereof.The exosome secreted by 293T cells serves as a natural nano-carrier, an FAP antibody with fibroblast targeting performance is modified on the exosome membrane surface through a copper-free click chemical method, and the exosome membrane surface is modified through a copper-free click chemical method; an anti-fibrosis drug PFD is efficiently loaded into the exosome by adopting an ultrasonic method, so that an engineered exosome system (293Texo antiFAP + PFD) with targeted recognition and drug delivery functions is constructed. The system is delivered to the lung in an aerosol inhalation mode, accurate enrichment and stable release of PFD at the pulmonary fibrosis focus can be achieved, and therefore lung tissue structure damage and collagen deposition are effectively relieved, and the anti-fibrosis curative effect is remarkably improved. According to the technology, the problems of low drug delivery efficiency, large side effect, poor targeting property and the like in traditional treatment are solved, and a safe, efficient and accurate treatment strategy is provided for pulmonary fibrosis.

The present invention relates to a process for isolating Small Extracellular Vesicles secreted by umbilical cord blood mononuclear cells (UCBMNCs) and compositions comprising said Small Extracellular Vesicles, which are useful to be applied to autoimmune diseases therapeutics or prophylactics and / or cosmetic purposes.The proposed process for isolating UCBMNCs Small Extracellular Vesicles comprises three main steps: i) a first step of sequential centrifugation, ii) a second step of microfiltration combined with ultrafiltration (UF), and iii) a third step of size exclusion chromatography (SEC) and aims to achieve highly pure Small Extracellular Vesicles and in a higher yield.The SEVs compositions comprise specific type of proteins, RNA and lipids, that enables them to be very effective when applied to inflammatory and autoimmune diseases therapeutics, such as psoriasis, lupus, atopic dermatitis, eczema, etc. and also to cosmetic or prophylactic compositions.Therefore, the present invention lays in the technical domain of pharmaceuticals, medicine, cosmetics, research and development in cellular biology and appliances thereof.

The invention provides a bispecific antibody targeting PVRIG and PDL1 and an application of the bispecific antibody. The bispecific antibody comprises a first antigen binding region and a second antigen binding region, wherein the first antigen binding region has PVRIG molecular binding activity; and a second antigen binding region, wherein the second antigen binding region has PDL1 molecule binding activity; wherein the first antigen binding region is connected with the second antigen binding region. The anti-PVRIG-PDL1 bispecific antibody prepared by the invention has high affinity, can be efficiently combined with human PVRIG and PDL1 proteins, effectively blocks the combination of the PVRIG and CD112 and the combination of the PDL1 and PD1, contributes to enhancing the killing ability of human peripheral blood mononuclear cells (PBMC) to tumor cells, and improves the function of secreting cytokines by CD8T cells.

The invention provides a Artemisia anomala aqueous extract and application thereof, the Artemisia anomala aqueous extract is obtained by sequentially extracting cyclohexane, dichloromethane, ethyl acetate, n-butyl alcohol and water, and the chemical properties of index components are not significantly changed. The Artemisia anomala aqueous extract can promote B cells to secrete IgA, IgM and IgG in vitro. In addition, the Artemisia anomala aqueous extract can effectively slow down the weight loss of mice caused by influenza viruses, and the weight rise is dose-dependent; meanwhile, the lung index after influenza virus infection can be reduced, the thymus index can be improved, the levels of various antibodies and influenza virus specific neutralizing antibodies in serum can be enhanced, and the effects of resisting influenza virus and enhancing humoral immunity can be achieved. Therefore, the Artemisia anomala aqueous extract shows a good immunological enhancement effect in vivo and in vitro, and a new thought is provided for application in the field of immunological enhancement.

A method of identifying a biomarker present in a defined category of tissue in an organism at an elevated level when compared to a level in at least one different category of tissue, wherein the biomarker is detectable on extracellular vesicles secreted from cells of the defined category of tissue. The method comprises the steps of: (i) identifying a candidate biomarker; (ii) providing a binding agent capable of specifically binding to the candidate biomarker identified in step i. (iii) detecting the presence of a candidate biomarker on extracellular vesicles obtained from a sample of defined categories of tissue by binding a binding agent to the candidate biomarker in the sample, where the candidate biomarker is not present on the extracellular vesicles obtained from the sample of defined categories of tissue, compared to the extracellular vesicles from at least one different category of tissue of the organism, extracellular vesicles from defined categories of tissue preferentially bind to a binding agent; and (iv) selecting the candidate biomarker as a biomarker present at an elevated level in the defined category of tissue. Also provided are methods of enriching a biological sample comprising a mixture of extracellular vesicles to generate an enriched fraction of extracellular vesicles from defined categories of tissue. Also provided are methods of analyzing the contents of extracellular vesicles in an enriched fraction of extracellular vesicles from defined categories of tissue.

The application discloses application of ostruthin in enhancing CAR-T cell anti-tumor function, belongs to the technical field of biological medicine, and the ostruthin can promote cell proliferation, inhibit cell exhaustion, promote the secretion of cytokines related to killing cancer cells, and further enhance the anti-tumor function of CAR-T cells in vivo and in vitro as a cell enhancer of CAR-T cells; experimental results show that when ostruthin is combined with CAR-T cells for anti-tumor treatment, compared with ostruthin or CAR-T cells alone, the combination of the two can significantly inhibit the growth of solid tumors. The application provides a new technical means for improving the tumor treatment effect of CAR-T cell immunotherapy.

A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor or agent. Exemplary compositions inhibit cellular secretion of aP2 or bind to circulating aP2, thereby reducing the level or activity of aP2 in blood or serum.

A biologic composition responsive to inflammation has an allograft scaffold matrix for injection or implantation. The allograft scaffold matrix has donor quiescent and / or senescent cells. The donor quiescent and / or senescent cells react in response to signaling of inflammation from host cells or matrix. The reaction to signaling causes the donor quiescent and / or senescent cells to secrete anti-inflammatory cytokines and secrete exosomes to initiate regeneration of the area of the inflammation. The biologic composition further has a cryoprotectant. The cryoprotectant is a polyampholyte, preferably the polyampholyte is an ε-poly-L-lysine. The cryoprotectant is not DMSO or glycerol based. The cryoprotectant is suitable for direct implantation without washing from the allograft scaffold matrix in either a diluted or non-diluted state.

A method for producing spheroids and cellular by-products of spheroids, such as extracellular vesicles, is provided. The method includes providing a bioreactor having a cavity for culturing cells, inserting the cells into the cavity to form spheroids, and perfusing cell culture medium through the cavity to culture the spheroids. The porous scaffold may be dissolvable or indissolvable, and cells are seeded into the pores of the porous scaffold, where they aggregate to form spheroids. The bioreactor is continuously perfused for large-scale spheroid production, allowing for the recovery of spheroids and / or extracellular vesicles or other elements from the cell secretome.

The present disclosure relates to a Treg-cell-targeting IL12 fusion protein, a corresponding nucleic acid molecule, vector, cell and pharmaceutical composition, a corresponding production method, a corresponding method for treating tumors, and the pharmaceutical use. Relative to a systemic immune system, the Treg-cell-targeting IL12 fusion protein of the present disclosure selectively activates the tumor microenvironment, especially inducing the secretion of IFNg by intratumoral Treg cells, thereby reducing or eliminating the immunosuppressive effect thereof.